Challenges in the Treatment of Xanthoma Disseminatum: Improvement in Disfiguring Facial Lesions with Cladribine and Brief Updated Literature Review
Open Access
- 1 June 2025
- journal article
- case report
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 1639-1644
Abstract
Xanthoma disseminatum (XD) is a rare normolipidemic mucocutaneous xanthomatosis that falls within the spectrum of cutaneous non-Langerhans cell histiocytosis. The management of XD poses significant challenges due to the limited availability of clinical data. Here, we report a case of XD with disfiguring facial involvement that showed marked improvement following treatment with cladribine. The patient tolerated the treatment well, with no significant adverse effects observed except for a transient decrease in white blood cell count, which normalized after symptomatic treatment with appropriate oral medications. Additionally, we provide an updated review of the literature on the use of cladribine in XD. Through this case report and literature review, we aim to underscore both the potential benefits and limitations of cladribine therapy for patients with XD. Furthermore, we emphasize the critical importance of effective interdisciplinary collaboration between dermatology and oncology for the optimal management of this condition.Keywords
This publication has 18 references indexed in Scilit:
- Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectivenessNeurological Sciences, 2024
- Successful treatment of xanthoma disseminatum with pulsed dye laser: A case reportAustralasian Journal of Dermatology, 2024
- Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2023
- Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysisNeurological Sciences, 2023
- Xanthoma disseminatum: rare normolipidaemic mucocutaneous xanthomatosisClinical and Experimental Dermatology, 2021
- Langerhans cell histiocytosis in childrenJournal of the American Academy of Dermatology, 2018
- Xanthoma disseminatumThe Lancet, 2018
- Xanthoma disseminatum: improvement in disfiguring facial lesions with cladribineJournal of the European Academy of Dermatology and Venereology, 2015
- Xanthoma DisseminatumArchives of Dermatology, 2011
- A Child with Both Langerhans and Non‐Langerhans Cell HistiocytosisPediatric Dermatology, 2002